ArticleFrontiers in immunology2021
Novel Immune Infiltrating Cell Signature Based on Cell Pair Algorithm Is a Prognostic Marker in Cancer.
Article in Frontiers in immunology, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 31 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
31 citing papers in PubMed.
- Characterization of Immune Infiltrating Cells in Bladder Urothelial Carcinoma and Its Clinical Significance.Cancer medicine · 2026Article
- The value of GULP1 in cancer prognosis and immunotherapy, validated from pan-cancer analysis to pancreatic cancer.Scientific reports · 2025Article
- A Comprehensive Analysis of Epoxide Hydrolase 2 (EPHX2) in Pan-Cancer.Cancer reports (Hoboken, N.J.) · 2025Article
- Identification and Validation of Prognostic Genes Related to Histone Lactylation Modification in Glioblastoma: An Integrated Analysis of Transcriptome and Single-cell RNA Sequencing.Journal of Cancer · 2025Article
- Comprehensive pan‑cancer analysis of MTDH for human tumor prognosis and as an immunological biomarker including breast and kidney cancer.Oncology letters · 2024Article
- Identification of prognostic risk score of disulfidptosis-related genes and molecular subtypes in glioma.Biochemistry and biophysics reports · 2024Article
- The prognostic and immunological role of MCM3 in pan-cancer and validation of prognosis in a clinical lower-grade glioma cohort.Frontiers in pharmacology · 2024Article
- Inhibition of PCSK9: A Promising Enhancer for Anti-PD-1/PD-L1 Immunotherapy.Research (Washington, D.C.) · 2024Review
- Article
- Multi-omics analysis of the oncogenic value of copper Metabolism-Related protein COMMD2 in human cancers.Cancer medicine · 2023Article
- Article
- Single-Cell Sequencing Reveals Necroptosis-Related Prognostic Genes of Glioblastoma.Oxidative medicine and cellular longevity · 2023Article
- Novel exosome-related risk signature as prognostic biomarkers in glioblastoma.Frontiers in immunology · 2023Article
- Tumor-secreted lactate contributes to an immunosuppressive microenvironment and affects CD8 T-cell infiltration in glioblastoma.Frontiers in immunology · 2023Article
- Pancancer Analysis Revealed the Value of RAC2 in Immunotherapy and Cancer Stem Cell.Stem cells international · 2023Article
- Pan-cancer and single-cell analysis reveal the prognostic value and immune response of NQO1.Frontiers in cell and developmental biology · 2023Article
- PTX3 mediates the infiltration, migration, and inflammation-resolving-polarization of macrophages in glioblastoma.CNS neuroscience & therapeutics · 2022Article
- Pericyte mediates the infiltration, migration, and polarization of macrophages by CD163/MCAM axis in glioblastoma.iScience · 2022Article
- Activation of the chemokine receptor 3 pathway leads to a better response to immune checkpoint inhibitors in patients with metastatic urothelial carcinoma.Cancer cell international · 2022Article
- Targeting the gut and tumor microbiota in cancer.Nature medicine · 2022Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Tumor-infiltrating immune cells (TIICs) have become an important source of markers for predicting the clinical outcomes of cancer patients. However, measurements of cellular heterogeneity vary due to the frequently updated reference genomes and gene annotations. In this study, we systematically collected and evaluated the infiltration pattern of 65 immune cells. We constructed the Immune Cell Pair (ICP) score based on the cell pair algorithm in 3,715 samples and across 12 independent cancer types, among which, the ICP score from six cancer types was further validated in 2,228 GEO samples. An extensive tumorigenic and immunogenomic analysis was subsequently conducted. As a result, the ICP score showed a robust reliability and efficacy in predicting the survival of patients with gliomas, in pan-cancer samples, and six independent cancer types. Notably, the ICP score was correlated with the genomic alteration features in gliomas. Moreover, the ICP score exhibited a remarkable association with multiple immunomodulators that could potentially mediate immune escape. Finally, the ICP score predicted immunotherapeutic responses with a high sensitivity, allowing a useful tool for predicting the overall survival and guiding immunotherapy for cancer patients.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.